The Michael J. Fox Foundation Grants Second Award to NeuroHealing for Clinical Trial of NH004 for Sialorrhea Control in Parkinson’s Disease
May 23, 2011
NeuroHealing Announces Orphan Drug Designation in Europe for NH001 for the Treatment of Patients Following a Moderate or Severe Traumatic Brain Injury
May 16, 2011
NeuroHealing Announces Strategic Master Services and Investment Agreement with Cato BioVentures
May 9, 2011
NeuroHealing Announces Issuance of U.S. Patent for Brain Injury Treatment
May 3, 2011
NeuroHealing Announces Treatment of First Patient in NH001 Coma Clinical Study
December 10, 2010
Positive Results of Phase II Clinical Study for the Treatment of Sialorrhea Presented at Parkinson’s Disease Congress
November 3, 2010
NeuroHealing Awarded Qualified Therapeutic Development Project Grant
October 13, 2010
NeuroHealing Receives Notice of Allowance from the U.S. Patent and Trademark Office for a New Treatment for Premature Ejaculation
April 14, 2010
NeuroHealing Pharmaceuticals Announces Publication Supporting the Use of NH001 to Treat Patients in a Coma and Issuance of NH001 Patent
